• Forge Inks Roche Deal For Antibiotic Aimed at Drug-Resistant Infections

    10 days ago - By Xconomy

    Forge Therapeutics has set an agreement with Roche that gives the Swiss pharma giant the option to license a new antibiotic Forge is developing to treat serious drug-resistant bacterial lung infections. This week the preclinical-stage San Diego-based biotech announced that under the deal Forge will retain control of the program, FG-LpxC LUNG, until Roche decides whether to exercise its exclusive option. Forge's experimental antibiotic is intended to address infections most commonly acquired by people with weakened immune systems and chronic lung diseases while in the hospital, such as...
    Read more ...